Business Wire

SAMSUNG-ELECTRONICS

17.1.2023 10:06:47 CET | Business Wire | Press release

Share
Samsung Introduces the 200-Megapixel Image Sensor for the Ultimate High Resolution Experience in Flagship Smartphones

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its latest 200-megapixel (MP) image sensor, the ISOCELL HP2, with improved pixel technology and full-well capacity for stunning mobile images in tomorrow’s premium smartphones.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005554/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Samsung Introduces the 200-Megapixel Image Sensor for the Ultimate High Resolution Experience in Flagship Smartphones (Graphic: Business Wire)

"The Samsung ISOCELL HP2 harnesses Samsung's high-resolution image sensor technologies and know-how at the cutting edge for epic details," said JoonSeo Yim, Executive Vice President of Sensor Business Team at Samsung Electronics. "Our leadership comes from innovative pixel technologies that allow our sensors to go beyond the number and size of pixels. We will continue to open new horizons and solidify our presence in the expanding ultra-high-resolution sensor market."

The ISOCELL HP2 packs 200-million 0.6-micrometer (μm) pixels in a 1/1.3” optical format, a sensor size that is widely used in 108MP main smartphone cameras. This enables consumers to enjoy even higher resolutions in the latest high-end smartphones without larger camera bumps in their devices.

With Samsung’s advanced pixel-binning technology, Tetra2pixel, the HP2 adds more versatility to the camera as it simulates different pixel sizes to accommodate varying lighting levels. When in low-lit environments, the sensor transforms either into a 1.2μm 50MP or 2.4μm 12.5MP image sensor by binding four to 16 neighboring pixels. For fuller 8K video, approximately at 33MP, the HP2 switches to 1.2μm 50MP mode to minimize cropping and capture more of the scene. Filming 8K at 30 frames-per-second (fps), a wide field of view along with bigger pixel size can produce sharp cinematic videos.

Washed out pictures from brightly lit environments can be significantly reduced with the HP2, thanks to Samsung’s new Dual Vertical Transfer Gate (D-VTG) technology. In a photo diode within each pixel, a voltage transfer gate is placed on the bottom to transport electrons from the pixels to the logic layer. With high precision, D-VTG adds a second transfer gate in the pixel, boosting the pixel’s full-well capacity by more than 33 percent. With more electrons stored and efficient signal transfers, this method can reduce overexposure and enhance color reproduction, especially in bright light conditions

In low-lit settings, the HP2’s auto-focusing is taken to the next level with Super QPD, which allows the sensor to use all its 200-million pixels for focusing agents. The ample amount of focusing agents are grouped by four adjacent pixels to recognize both horizontal and vertical pattern changes that delivers faster and more accurate auto-focusing. Utilizing the rich pattern data along with the sheer number of reference points, the new sensor is capable of fast auto-focusing, even in a dimly lit environment.

For superb HDR performance, Samsung is introducing the DSG feature for the first time in 50MP mode which applies two separate conversion values to the analog signal received at the pixel level. In addition, the Smart-ISO Pro, an HDR solution that merges different levels of ISO readouts from a single exposure, allows the camera to take 12.5MP images and 4K at 60fps video in HDR.

The Samsung ISOCELL HP2 has entered mass production.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005554/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye